Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVENT: Erlotinib Neoadjuvant in Stage III NSCLC
NCT01857271Phase 2Terminated
- Sponsor
- Albert Einstein College of Medicine
- Start
- Nov 2013
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Albert Einstein College of Medicine. Started Nov 2013; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01857271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01857271.